KYTX
Kyverna Therapeutics Inc.
$6.97
+$0.22(+3.26%)
54
Overall
60
Value
66
Tech
36
Quality
Market Cap
$250.82M
Volume
368.43K
52W Range
$1.78 - $8.45
Target Price
$20.50
Order:
Income Statement
| Metric | Trend | Chart | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|
| REVENUE | |||||
| Total Revenue | $7.0M | -- | -- | ||
| Total Revenue | $7.0M | -- | -- | ||
| GROSS PROFIT | |||||
| Gross Profit | $7.0M | -- | -- | ||
| OPERATING EXPENSES | |||||
| Operating Expenses | $36.4M | $62.4M | $142.6M | ||
| Research & Development | $28.4M | $49.9M | $112.5M | ||
| Research Expense | $28.4M | $49.9M | $112.5M | ||
| Selling, General & Administrative | $8.0M | $12.5M | $30.1M | ||
| General & Administrative Expenses | $8.0M | $12.5M | $30.1M | ||
| Salaries & Wages | -- | -- | $8.4M | ||
| Depreciation & Amortization | -- | -- | $1.2M | ||
| Depreciation & Amortization | -- | -- | $1.2M | ||
| Amortization | -- | -- | $949.0K | ||
| Other Operating Expenses | -- | -- | $-10.4M | ||
| OPERATING INCOME | |||||
| Operating income | $-29.4M | $-62.4M | $-142.6M | ||
| EBITDA | -- | $-58.5M | $-125.2M | ||
| NON-OPERATING ITEMS | |||||
| Interest Expense (Non-Operating) | $65.0K | $187.0K | $142.0K | ||
| Intinc | $565.0K | $2.3M | $15.4M | ||
| Net Non-Operating Interest Income/Expense | $500.0K | $2.1M | $15.4M | ||
| Other Income/Expense | $9.0K | $-55.0K | $90.0K | ||
| Other Special Charges | $-9.0K | $-55.0K | $-90.0K | ||
| PRE-TAX INCOME | |||||
| EBIT | -- | $-60.2M | $-127.3M | ||
| Pre-Tax Income | $-28.9M | $-60.4M | $-127.3M | ||
| NET INCOME | |||||
| Net Income | $-28.9M | $-60.4M | $-127.5M | ||
| Net Income (Continuing Operations) | $-28.9M | $-60.4M | $-127.5M | ||
| Net Income (Discontinued Operations) | $-28.9M | $-60.4M | $-127.5M | ||
| Net Income (Common Stockholders) | $-28.9M | $-60.4M | $-127.5M | ||
| Normalized Income | -- | $-44.4M | $-126.1M | ||
| TOTALS | |||||
| Total Expenses | $36.4M | $62.4M | $142.6M | ||
| SHARE & EPS DATA | |||||
| Average Shares Outstanding | $455.5K | $673.6K | $38.3M | ||
| Average Shares Outstanding (Diluted) | $455.5K | $673.6K | $38.3M | ||
| Shares Outstanding | $43.2M | $43.2M | $43.2M | ||
| Basic EPS | $-63.43 | $-89.61 | $-3.33 | ||
| Basic EPS (Continuing Operations) | $-63.43 | $-89.61 | $-3.33 | ||
| Diluted EPS | $-63.43 | $-89.61 | $-3.33 | ||
| Diluted EPS (Continuing Operations) | $-63.43 | $-89.61 | $-3.33 | ||
| OTHER METRICS | |||||
| Other Gand A | $8.0M | $12.5M | $30.1M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KYTX | $6.97 | +3.3% | 368.43K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Kyverna Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW